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Abstract
According to the current epidemiological studies, 3% of the world 
population is infected with hepatitis C virus (HCV). The gold standard 
of therapy, at this time, is neither effective in a high percentage of 
patients, nor with all genotypes .Furthermore, it is associated with 
significant side effects and high cost. Therefore, new therapeutic strat-
egies have been investigated, or in the early process of development. 
These include: direct acting antiviral agents (DAAs) and immune-
based therapy. Four DAA molecules have been already approved by 
the FDA. Immune based therapy aims at augmenting host immunity, 
thus prevention of infection, and clearance of the virus in subsequent 
re-infection. Boosting T cell responses and activating humoral immune 
reaction have been targeted in the development of novel fighting 
tools. The most intensively studied immune-therapeutic strategies are: 
1) vaccines; either therapeutic or prophylactic, 2) dendritic cells (DCs) 
immunotherapy, 3) antagonists of T cell inhibitory factors, 4) anti-HCV 
neutralizing antibodies (nAbs), 5) antagonists for Toll-like receptors 
(TLRs), and 6) caspase inhibitors.
Globally, 170 million people are chronically infected with HCV, [1]. 
Furthermore, it is estimated that the world reservoir of HCV infected 
individuals is in a steady increase, which is not limited to developing 
countries [2].
Despite a long battle within the field of control and treatment, HCV 
infection remains to be a serious health problem. That is due to the 
belatedly complications of life-threatening liver diseases, including 
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livercirrhosis and hepatocellular carcinoma, [3]. HCV 
has also been incriminated among the most impor-
tant causative factors for type II mixed cryoglobuli-
nemia (MC) [4].
 Current gold-standard therapy for HCV infection is 
weekly injections of pegylated interferon combined 
with daily oral ribavirin. In addition to being ex-
pensive, this therapy is fraught with significant side 
effects. Response varies with different genotypes. 
A sustained virologic response (SVR) of 40- 50% 
is achieved with genotype 1. Higher SVR rates are 
achieved in patients infected with HCV genotypes 
2, 3, 5, and 6 (up to about 80%, and better for 
genotype 2 than for genotypes 3, 5, and 6, and 
intermediate SVR rates were achieved in those with 
HCV genotype 4 [5]. Given these results, explora-
tion of new therapeutic strategies with higher ef-
ficacy and less side-effect is urgently needed. 
In recent years, researchers have focused their ef-
forts on developing novel molecules with antivi-
ral effect, as well as emphasizing immune-based 
therapy. Four molecules with anti- HCV effect are 
now available; boceprevir, telaprevir, sofosbuvir and 
simeprevir [6-7]. In spite of the capability of these 
molecules to increase SVR rates, it is even far more 
costly, and is associated with potential drug-drug 
interactions and substantial side effects.
Immune-based strategies can represent an intriguing 
alternative as therapeutic as well as prophylactic ap-
proach. When HCV infection occurs, nearly 15-30% 
of acutely infected individuals can spontaneously 
eradicate the virus [8]. In addition, significant levels 
of innate immunity to HCV have been reported in 
studies of the chimpanzee model [9] and in stud-
ies of reinfections in intravenous drug users [10]. 
These findings have highlighted the fundamental 
role of innate immune response in the control and 
resolution of HCV infection. Such pessimistic view 
has also been moderated by significant advances in 
our understanding of the immunological correlates 
and mechanisms underlying the successful control 
of viral infection [11]. All these findings have led to 
a conclusion that prevention and/or cure of HCV is 
possible if similar immune responses can be elicited. 
T cell responses have been targeted in the devel-
opment of novel combating tools, and therapeutic 
strategies for activating humoral immune responses 
have also been under development.
Immunological strategies for 
prevention/treatment  
of chronic HCV
Chronic HCV infection cases resistant to conven-
tional therapies, or those who are relapsers might 
be treated by immunotherapy-based strategies. 
These strategies may also endow with a safe, ef-
fective and affordable prophylactic approach, pro-
viding the best long-term hope for controlling the 
global epidemic, thereby decreasing the burden on 
healthcare systems.
In this review, we will discuss immunological strate-
gies that could be used as therapeutic and/or pro-
phylactic agents for HCV infections. These include 
HCV vaccines, DCs immunotherapy, antagonists of 
T cell inhibitory factors, anti-HCV nAbs, cytokines 
and chemokines, agonists for TLRs, and caspase in-
hibitors, figure (1).
Vaccines
The development of vaccines against HCV is ham-
pered by several challenges. First of all, is the ge-
netic heterogeneity which is a hallmark of HCV as 
an RNA virus [13]. Moreover, there are technical 
limitations in the study of HCV, mainly as regards 
the limited availability of convenient small animal 
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models other than the chimpanzee, mimicking HCV 
infection in humans. Another challenge was the dif-
ficulty of growing the virus in cell culture, a problem 
which has been recently overcome [14].
A successful HCV vaccine should address viral het-
erogeneity, cover the various genotypes and quasi-
species of HCV, and must incorporate epitopes from 
HCV structural proteins in their correct three-dimen-
sional conformations, to induce the production of 
high titers of broad nAbs. It must also incorporate 
HCV-specific T-cell epitopes from HCV nonstructur-
al proteins, to elicit strong cellular responses [15-17].
Both prophylactic and therapeutic vaccine candi-
dates have been developed. The general principals 
pertaining to the different vaccination strategies in-
clude: recombinant protein vaccines, including the 
recombinant yeast-based vaccine candidates, virus-
like particles vaccines, peptides vaccines, DNA vac-
cines, viral vector vaccines, and DCs- based vaccines. 
DC-based vaccines will be discussed later. The most 
recent achievement in the development of vaccines 
in the other categories are shown in table 1.
Candidate vaccination approaches which are con-
sider the most recent, the most considered and, 
perhaps, the most promising are: the recombinant 
protein vaccines [20] the adenovirus-based vaccine, 
[29] virus-like particles- based [21] and the DNA vac-
cines candidates [25]. 
As the resolution of HCV infection is frequently as-
sociated with high quality cellular immunity and the 
production of nAbs, conceivably, combining the ap-
proaches that p rime both humoral and cellu-
lar immunity would protect more efficiently against 
HCV challenge. It would be very interesting to in-
vestigate, in a prime-boost regimen, a combination 
of vaccines; the first to target cellular immune re-
sponses, and the second to target nAbs formation. 
The first could be the adenovirus-based vaccine 
[29] while the second could be a virus like particles- 
based vaccine [21]. Although this concept remains 
to be tested in suitable animal models and/or clinical 
trials, it should be possible to develop vaccines with 
at least partial efficacy against HCV-induced chronic 
liver disease [21]. 
 
Figure 1. Strategies of immune-based 
therapy [12].
THE INTERNATIONAL ARABIC JOURNAL 
OF ANTIMICROBIAL AGENTS
2014
Vol. 4 No. 1:1
doi: 10.3823/743
This article is available from: www.iajaa.org4 Received on 28 April 2014; accepted after revision on 24 May 2014 
Table 1. The progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
Strategy Vaccine Manufacturer Aim Challenge inoculum
Study model 
(Phase)
Outcome Ref
Recombinant 
protein
Chiron Corp 
HCVE1/E2 
vaccine
NIAID
Novartis Prophylactic
Recombinant E1 and 
E2 proteins with MF59 
adjuvant.
Human
Phase I 
Phase II 
planned 
2012-2013
Neutralizing 
antibodies to 
hepatitis C
18, 19
Recombinant
protein
Recombinant gpE1/gpE2 
from a single strain (HCV1 
of genotype 1a).
Human
2013
Minority of 
vaccinees, elicited 
broad cross-
neutralization 
against all HCV 
genotypes
20
Virus like 
particles (VLP)
Bivalent HBV/
HCV vaccine
Prophylactic
Chimeric HBV–HCV E1-S 
and E2-S proteins.
Rabbit 
2013
Strong specific Ab 
response against 
the HCV and HBV 
envelope proteins 
21 
Virus like 
particles (VLP)
HCV-specific 
plasmo-
retroVLPs
Prophylactic
Plasmid DNA forming 
VLPs pseudotyped with 
HCV E1 and E2 envelope 
glycoproteins.
Mice
2013
Induce broad 
cellular and humoral 
immune responses.
22 
Peptide IC41 Intercell AG Therapeutic
HCV peptides with 
polyarginine.
Human
Phase II
2012 
Safe and well 
tolerated. Specific T 
cell responses. Weak 
viral load reduction. 
23,  
24
DNA vaccines
 (Chron            
Vac-c)
Inovio Therapeutic
DNA based vaccine 
CHRONVAC- C® in 
collaboration with 
elecroporation, followed 
by Standard of care 
therapy.
Human
Phase II
2013
Excellent safety 
profile. Elimination/
reduction of HCV 
viral load. 
25
DNA vaccines INO 800 HCV Inovio Therapeutic
Synthetic multi-antigen 
DNA vaccine covering 
HCV genotypes 1a and 1b 
and targeting the antigens 
NS3/4A.
Phase I/IIa 
(4Q 2013)
26
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Dendritic cell immunotherapy
In the last decade, considerable progress has been 
made in the field of DC biology [30]. Furthermore, 
promising results have been published for immuni-
zation against the human immunodeficiency virus, 
[31] and Epstein-Barr virus (32). On April, 2010 the 
DC vaccine PROVENG was approved by the FDA to 
treat prostate cancer [33]. Consequently, a scientific 
focus has been brought to the critical effect of DCs 
as an important element of immune-based strate-
gies for both treatment of, and prophylaxis against 
HCV.
A therapeutic DC vaccine, in addition to the potent 
capability of T cells priming, is supposed to bypass 
the suboptimal microenvironment and/or dimin-
ished DC function in chronic hepatitis C patients in 
vivo. DC-based vaccines are also expected to be en-
couraging as prophylactic for high-risk populations 
by induction of both CD8+  T cells and CD4+  Th 
cells [34].
DC-based vaccine development has used a number 
of proteins as antigens either separate or in various 
combos. They are HCV proteins both structural and 
non-structural, as core, [35] NS3, [36] NS4a, [37] 
NS5, [38] and NS5b [39]. HCV-like particles [40] and 
the most recent is HCV pseudoparticles (HCVpp). 
[41] 
DC-based vaccine development has also used a 
strategy which is based upon ex vivo  stimulated 
and matured DC loaded with HCV specific antigens, 
which are then delivered into host [42]. 
Starting from 2001 there is a large body of litera-
ture involving the use of various vehicles for loading 
DCs with various HCV antigens for the purpose of 
developing potent therapeutic or prophylactic vac-
cine candidate, or of developing model systems to 
study HCV-DCs interaction, figure 2. They are; ad-
enoviral vector, [43] recombinant adeno-associated 
virus (rAAV), [37] anthrax toxin fusion protein, [44] 
vaccinia virus, [45] lentivirus, [46] pesti virus, [47] 
microbeads vectors, [48] a protein delivery based 
on a short amphipathic peptide carrier; Pep1 [49], 
extra domain A from fibronectin (EDA), [50] and the 
lipid Pam2Cys [51]. 
Recently, dendritic cell (DC) -based vaccines against 
HCV has been created. Some of DCs vaccination 
strategies were even developed into clinical trials 
targeting chronic HCV subjects [52-54].
Viral vector TG4040 Transgene Therapeutic
MVA vector expressing 
HCV antigens including 
NS3, NS4, and NS5B, 
followed by SOC
Phase II
Well tolerated, 
decline in HCV viral 
load and increased 
early response rates 
of SOC. 
27,  
28
Viral vector
Adenovirus-
based vaccine
Prophylactic
HAd6 and ChAdCh3, 
expressing nonstructural 
proteins of HCV
Human
Phase I
Safe and well 
tolerated.
Highly immunogenic 
response, with the 
induction of robust, 
cross-reactive and 
sustained CD4+ 
and CD8+ T cell-
mediated responses.
29
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Figure 2. Antigen loading on 
DCs, [12].Vehicles for loading 
DCs with HCV antigens, 
including: adenoviral vector, 
rAAV, anthrax toxin fusion 
protein, vaccinia virus, lentivirus, 
pesti virus, microbeads vectors, 
a protein delivery based on 
a short amphipathic peptide 
carrier; Pep1, EDA, and the lipid 
Pam2Cys.
 
Antagonists of T cell inhibitory 
factors
T cells are exhausted and overexpress inhibitory 
molecules in chronic HCV infection. These include 
cytotoxic T lymphocyte antigen-4 (CTLA-4), [55] 
programmed death-1 (PD-1) inhibitory receptor, [56] 
B7 family member B7-H4, [57] T cell immunoglobu-
lin and mucin domain-containing protein 3 (Tim-3), 
[58] and lymphocyte activation gene-3 (LAG-3) [59]. 
Interaction of these molecules with their cognate 
ligands on various cells types result in reduced T cell 
propagation and function, [60] together with toler-
ance to the antigens’ exposure [61]. Indeed, one of 
the primary goals of immune- therapy is the func-
tional reversal, or reactivation, of tolerized T cells 
in settings of chronic antigen exposure. Novel HCV 
treatments based on blockade of these inhibitory 
molecules are being investigated. 
Tremelimumab is a fully human IgG2 monoclonal 
antibodies (mAb) directed against CTLA-4. Clinical 
trials for HCV disease are still underway [62]. 
Blockade of PD-1 signaling can restore function to 
exhausted virus-specific CD8 T cells. [63] MDX-1106, 
is a fully human antibody also known as ONO-4538, 
and CT-011. It interacts with PD-1 receptor, and is 
being developed as treatment for cancer disease 
and for therapy of chronic HCV infection. [64] Clini-
cal studies to evaluate the use of CT-011 in HCV 
disease have been initiated [65]. 
Co-expression of PD-1 and CTLA-4 was observed in 
liver-infiltrating lymphocytes, but not in peripheral 
blood lymphocytes, suggesting the phenotypic dif-
ferences of virus-specific CD8+ T cells in different 
in vivo compartments. PD-1 and CTLA-4 express-
ing HCV-specific T cells were profoundly dysfunc-
tional [66]. It is important and possible to consider 
the combination of PD-1 and CTLA-4 blockade for 
immunotherapy to enhance antiviral immune re-
sponses. [67]. Mbs interfering with the PD-1 and 
CTLA-4 pathways, [68] are currently being studied 
in clinical trials.
Silencing B7-H4 by small interfering RNA (siRNA) 
in activated hepatic stellate cells (HSC) restored the 
ability of T cells to proliferate, differentiate, and re-
gain effector recall responses. Furthermore, addi-
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tion of exogenous interleukin (IL)-2 reversed the T 
cell anergy induced by activated HSC [69]. 
Recent studies have shown that higher expression 
levels of dual Tim-3 and PD-1 has been reported to 
correlate with impaired Th1/Tc1 cytokine secretion 
and diminished cytotoxic potential. Their combined 
blockade of T cell immunoglobulin and mucin do-
main–containing molecule 3 (Tim-3) represents a 
potential target for novel immunotherapeutic ap-
proaches [70].
Studies have shown that inhibition of LAG-3 through 
Ab blockade can reverse the tolerogenic state, and 
partially restore effector function of immune cells 
[71].
 
Anti-HCV neutralizing 
antibodies
Recent reports of human monoclonal antibodies 
(nAbs) neutralizing genetically diverse HCV isolates 
and protecting against heterologous HCV quasispe-
cies challenge have validated the concept of the use 
of neutralizing antibodies to prevent HCV infection 
[72].
Current understanding of the nAbs response raised 
against HCV suggests that E2 is the major target, 
and that multiple epitopes within E2 may be tar-
geted by both linear -and conformation-dependent 
antibodies. Predominantly, these neutralization 
epitopes overlap with CD81-binding sites, [73] and 
clearly demonstrate a role in inhibition of entry. A 
number of anti-receptor Abs targeting SR-BI,  has 
been reported [74]. 
Given the potential antiviral effect of the antibodies, 
HCV has evolved multiple mechanisms for protec-
tion from antibody binding. These include glyco-
sylation of receptor, and lipid shielding [75]. More 
recently, HCV has been found capable of direct 
cell-to-cell transmission, which is largely resistant to 
antibody neutralization [76]. Finally, the high muta-
tion rate of HCV, constitutes a significant hurdle for 
nAbs development [77]. All these problems may be 
counter-balanced by selecting nAbs which target 
conserved and more accessible areas of viral parti-
cles, and/or by using mixtures of nAbs which target 
various key epitopes. In fact, it has been demon-
strated that combination therapy with nAb cocktails 
prevents escape variants for many viruses, including 
influenza, and others [78]. 
MBL-HCV1 is one of the monoclonal antibodies 
against the viral antigens. A phase I open-labelled, 
dose escalation study was performed in healthy 
adult volunteers. MBL-HCV1 was well-tolerated 
without any seriously adverse effects. Based on the 
favourable safety, tolerability and pharmacokinetics 
data, a phase II study of MBL-HCV1 in chronically 
infected HCV patients undergoing liver transplanta-
tion has been planned [79]. 
Another therapeutic Ab which targets host antigens 
is bavituximab. It is the first in a new class that 
targets and, preferentially binds, to phosphatidyl-
serine which is exposed on the surface of certain 
atypical animal cells, including cells infected with 
HCV [80]. Among clinical trials using bavituximab, it 
is currently being evaluated in randomized phase II 
clinical trial for therapy of chronic HCV infection and 
for HIV/HCV co-infection [81]. The available results 
are promising.
Cytokines and chemokines
Cytokines play an important role in the defense 
against viral infections. In HCV infection, cytokines 
are involved in either viral control or liver damage 
[82]. 
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Interferons-alpha ( IFNs-α ) is the only cytokine cur-
rently used in the treatment of chronic viral hepatitis 
[83]. On the other hand, ribavirin, a wide-spectrum 
antiviral agent used in combination therapy for hep-
atitis C, has immunomodulating effects that induce 
type 1 cytokine production [84]. 
In addition to IFNs-α, IFN-γ was shown to suppress 
HCV replication. A comparative analysis demon-
strated that IFN-γ exerted a more prolonged anti-
viral effect than IFN-α and IFN-β in the HCV RNA 
replicon system [85]. 
In addition, cytokines involved in the regulation of 
cytokine networks could be combined with cyto-
kine therapies to enhance the efficacy. In this con-
text, recombinant IL-2 was tested in patients with 
chronic HCV infection. However, IL-12 therapy was 
poorly tolerated and showed low efficacy as regards 
SVR [86].
Other anti-inflammatory cytokines such as IL-10 has 
also been attempted to reduce intrahepatic inflam-
mation severity. [87]. However, such therapies re-
main experimental, and their effectiveness is unclear.
From a theoretical standpoint Tc1-associated che-
mokine receptors may represent an interesting 
therapeutic target in the development of drugs for 
patients with chronic hepatitis unresponsive to an-
tiviral agents. Their aim being a reduction of liver 
inflammation and progression to fibrosis by block-
ing inflammatory cell migration into the liver [88]. 
Another important cytokine is the IFN-lambda, 
which is expected to become the next cytokine 
storm. It upregulates IFN-stimulated genes similar 
to IFN-alpha and -beta, but via a different receptor. 
There is also evidence that IFN-lambda affects the 
adaptive immune response [89]. Clinical studies as-
sessing safety and efficacy in the treatment of HCV 
with exogenous IFN-lambda3 are of great impor-
tance. Results suggest that IFN-lambda 3 treatment 
inhibits HCV replication and is associated with a 
limited side effect profile. However, hepatotoxicity 
has been described [90]. 
Pegylated interferon lambda was also evaluated 
in combination with DAAs [91]. This international 
Phase 2b trial enrolling patients with HCV genotype 
1 as well as a Japanese study enrolling patients with 
HCV genotype 1b infection [92], yielded extremely 
encouraging results. Both studies recommended 
further investigation in a larger population. 
Agonists for TLRs
Therapeutic applications of TLR to date have used 
two strategies. One involves synthetic versions of 
natural TLR ligands with optimized pharmacologic 
properties, and the other encompasses small mol-
ecule agonists derived from drug screening effort, 
(Amer F. 9th Arab Conference for Antimicrobial 
Agents. Beirut, Lebanon, 2012). 
TLR agonists are undergoing intense drug devel-
opment in different fields including chronic viral 
infections, oncology and vaccines. Agonists for 
TLR3, TLR7, TLR8 and TLR9 have shown promise 
as treatments for infectious diseases, especially viral 
infections. [93] A current knowledge is available on 
the use of many TLR agonists for HCV treatment, 
table 2. 
 
Caspase inhibitors
Increased apoptosis is a hallmark of active hepatitis 
C infection, and the level of hepatocyte apoptosis 
correlates with the histologic activity grade. It has 
been suggested that hepatocytes apoptosis may be 
a mechanism for viral shedding, so, inhibition of 
apoptosis could ameliorate HCV [101]. 
THE INTERNATIONAL ARABIC JOURNAL 
OF ANTIMICROBIAL AGENTS
2014
Vol. 4 No. 1:1
doi: 10.3823/743
© Under License of Creative Commons Attribution 3.0 License 9
Table 2. Anti-HCV drugs targeting TLRs R: references
Compound Target Company Status R Ref.
ANA975 TLR7 Anadys  Phase Ib [94]
ANA773 TLR7 Anadys  Phase IIa trials. [95]
CpG-ODN TLR9  Preclinical [93]
CpG10101 TLR9 Coley Phase II (discontinued) [96]
GS-9620 TLR7 Gilead 
Randomized,double-blind phase I.  
Active, not recruiting participants
[97]
Thymosin α1 TLR9, 2 on DCs & 
precursor T cells
SciClone Addition to an IFN-based regimen. [98]
Resiquimod TLR7/8 Spirig Pharma Ltd Double-blind, phase IIa studies. [99]
IMO-2125 TLR9 Idera
Dose escalation, proof of concept,  
phase I study. 
[100]
Figure 3. Apoptosis pathways, adapted from Mita, et al [102]. 
TCR: T cell receptor. HCV: hepatitis C virus, MHC: major histocompatibility complex, Fas: a transmembrane receptor of the tumor 
necrosis factor (TNF) receptor superfamily. FasL: Fas ligand, Bid: BH3 interacting-domain death agonist Bcl-XL: B-cell lymphoma-extra 
large. A transmembrane molecule in the mitochondria Cyt: cytochrome. APAF1: apoptotic protease activating factor 1
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Apoptosis is carried out via two pathways; death re-
ceptor–mediated pathway, and mitochondrial apop-
totic pathway, figure (3). HCV infection has been 
shown to influence both pathways [102].
The two pathways involve a sequence of reactions; 
the common end point of both is the activation of 
the cascade of the intracellular proteolytic enzymes 
caspases [103]. Since they are essential in cells for 
apoptosis, caspase inhibition often abrogates apop-
tosis. Consequently, interest as potential therapeutic 
targets, has emerged. Other factors were also found 
to contribute to caspases being an attractive thera-
peutic target in the setting of HCV. These include; i) 
caspases are activated in human biopsy specimens 
of chronic HCV patients, ii) their activation precedes 
morphological evidence of cell death, iii) about four 
times more apoptotic cells are detected in HCV-
infected liver tissue compared to control, iv) caspase 
inhibitors protect hepatocytes from death signals 
during HCV infection and organ stress, v) apop-
totic markers are decreased in HCV patients after 
treatment with caspase inhibitors, and vi) clinically, 
the ultimate result of caspase inhibition could be an 
overall reduction in the negative consequences of 
the host response to the virus infection (i.e., reduc-
tion in inflammation, apoptosis and fibrosis). [104 
So far, three caspase inhibitors have been tried for 
treatment of HCV infection; the pan-caspase inhibi-
tor ZVAD-fmk [105], emricasan/IDN-6556 [106], and 
MitoQ [107]. The first produced decreased mortality 
in the rat massive hepatectomy model of acute liver 
failure, while the other two were well tolerated and 
may halt disease progression to fibrosis or cirrhosis.
Conclusions 
Thanks to new advancements in medicine and dedi-
cated scientists, we now have an established body 
of knowledge regarding how the body reacts and 
interacts with HCV. We also know about the chain 
of events from the moment the virus enters the 
host, and how some infected patient eradicate the 
virus without medical interference.
The real challenge is how we can utilize this knowl-
edge to find new ways to prevent or cure this dis-
ease. As illustrated, this could happen by augment-
ing the body’s cellular immune response, thus pro-
viding the means to resist the virus as observed in 
the 15-30% of infected individuals who eradicated 
the virus spontaneously. 
There are several ways to promote the immune 
response to such levels, including preventive and 
corrective vaccines, targeting the DC cells that or-
chestrate functions of the immune system, finding 
antagonists of T cells inhibitory factors, anti-HCV 
nAb, identifying effective cytokines and chemo-
kines, agonists of TLR, and caspase inhibitors.
Many studies are currently underway or being con-
ducted and the results were placed across the ef-
fectiveness continuum. While some expressed the 
need for longer time to have meaningful results, 
others have shown promising and more positive 
outcomes. The later have been moved to clinical 
trials on human subjects.
HCV is a global disease, the morbidity and mortality 
rates are staggering.The cost of treating this disease 
is in upward spiral. However, the day of controlling 
this disease or even eradicating it is not a dream, 
but a true reality. 
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